A Phase 1 interventional study of HRS-2129 Tablet and Celecoxib capsule in Moderate Pain in Knee Osteoarthritis and Severe Pain in Knee Osteoarthritis, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.
Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 32nd largest by enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 10 in phase 1, and was the 124th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18–65
Belief BioMed (Beijing) Co., Ltd · Sites in China
Ages 40–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 40–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 15 · Phase 4 15
First in 2000; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 68 across 2,716 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 100 across the 115 interventional studies, 136 across the 21 observational. Of the 53 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 136 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shandong Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 5 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
9 of the studies in Osteoarthritis, Knee with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06570291Phase 3Wuxi Cellular Biopharmaceutical Group Ltd.Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | 2026-12 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07504562ShuGuang HospitalKnee Pain Ejiao Paste for Knee Osteoarthritis | 2026-12-31 |
| NCT06010979Tian HuaClinical Cohort Study of Knee Arthroplasty Assisted by Digital Technology | 2026-12-31 |
| NCT07736352China-Japan Friendship HospitalExploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants. | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 136 studies in Osteoarthritis, Knee with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HRS-2129 high dose group.
Drug: HRS-2129 Tablet · Drug: Celecoxib Capsule Placebo · Drug: HRS-2129 Tablet Placebo
HRS-2129 low dose group.
Drug: HRS-2129 Tablet · Drug: Celecoxib Capsule Placebo · Drug: HRS-2129 Tablet Placebo
Celecoxib group.
Drug: Celecoxib capsule · Drug: HRS-2129 Tablet Placebo
Placebo group.
Drug: Celecoxib Capsule Placebo · Drug: HRS-2129 Tablet Placebo
HRS-2129 tablet.
Celecoxib capsule.
Celecoxib capsule placebo.
HRS-2129 tablet placebo.
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores.
Time frame: At week 4.
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores.
Time frame: From baseline to Week 1, 2 and 3.
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) joint function subscale scores.
Time frame: From baseline to Week 1, 2, 3 and 4.
Change from baseline in the weekly mean (Week 1, 2, 3 and 4) of the index Knee Numerical Rating Scale (NRS) pain score (resting).
Time frame: From baseline to Week 1, 2, 3 and 4.
Change from baseline in the weekly mean (Week 1, 2, 3 and 4) of the index Knee Numerical Rating Scale (NRS) pain score (flat walking).
Time frame: From baseline to Week 1, 2, 3 and 4.
Change from baseline in the overall patient global assessment (PGA) of osteoarthritis condition using the 5-point Likert scale.
Time frame: From baseline to Week 1, 2, 3 and 4.
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale scores.
Time frame: From baseline to Week 1, 2, 3 and 4.
Change from baseline in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.
Time frame: From baseline to Week 1, 2, 3 and 4.
Treatment response: WOMAC pain subscale scores decreased by ≥ 30%, ≥ 50%, ≥ 70% from baseline.
Time frame: At Week 1, 2, 3 and 4.
Adverse events (AEs) occurred during the study.
To evaluate the safety and tolerability of HRS-2129 tablets.
Time frame: During the study, approximately 8 months.
Serious adverse events (SAEs) occurred during the study.
To evaluate the safety and tolerability of HRS-2129 tablets.
Time frame: During the study, approximately 8 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Jul 2026, 4 months.
Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 4 months is below that.
Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-2129
Shandong Suncadia Medicine Co., Ltd. →